PNPhilipp T. Neukam

Philipp T. Neukam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philipp T. Neukam has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A randomized, controlled experimental medicine study of the novel Kv7 channel opener azetukalner in individuals with major depressive disorder and anhedonia

    by Rachel Fremont, Philipp T. Neukam, Usha S. Govindarajulu, Jessica L. Ables, Sara Hameed, Marcella Corwin, Mackenzie B. Hargrove, Helena L. Chang, Sarah Boukezzi, Chris A. Kelly, et al.

    Major Depressive Disorder (MDD) is a common and debilitating disease. Kv7 potassium channels are relevant to reward processing and represent a novel target for depression and anhedonia. Azetukalner is a positive allosteric modulator of Kv7 channels. This phase II, randomized, double-blind, placebo-controlled trial assessed changes in brain reward function, clinical outcomes, and safety following treatment with azetukalner or placebo in individuals with MDD and anhedonia. The study included 60 participants with MDD and anhedonia in a current major depressive episode. Participants were randomized 1:1 to receive azetukalner (20 mg orally once daily with food) or placebo for 8 weeks. The primary endpoint was change in bilateral ventral striatum (VS) activity assessed by functional MRI (fMRI) during a reward task from baseline to week 8. Secondary endpoints included changes in depression severity and anhedonia measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) and Snaith-Hamilton Pleasure Scale (SHAPS). Of 60 participants, 29 were randomized to azetukalner and 31 to placebo. There was no significant difference in VS response to reward anticipation between groups. Compared to placebo, azetukalner was associated with numerical benefit on the MADRS and SHAPS that did not reach statistical significance. Most exploratory endpoints numerically favored azetukalner over placebo. Discontinuation rates due to adverse events were low and did not differ across groups. Despite not meeting the primary neuroimaging endpoint, secondary and exploratory outcomes suggested potential improvement in depressive symptoms and anhedonia. Trial Registration: Clinicaltrials.gov ID NCT04827901.

  • Open Access

    Functional connectivity of the locus coeruleus in anxiety and posttraumatic stress disorder reveals convergent mapping to the cingulate cortex and insula using ultra-high field 7 Tesla MRI

    by Philipp T. Neukam, Laurel S. Morris, Sarah C. Boukezzi, Yolanda I. Whitaker, Sarah B. Rutter, Vicki Soogrim, Nicholas Balderston, Yael Jacob, Prantik Kundu, Dennis S. Charney, et al.

    Cortical and subcortical correlates of anxiety and stress disorders have been well defined over recent decades. However, the role of the locus coeruleus (LC), which is responsible for synthesizing and releasing a majority of the brains’ norepinephrine, has been less widely studied. Here, we used ultra-high field 7T imaging with 400 μm³ voxel resolution to individually segment the LC. We performed a functional connectivity analysis to elucidate the relationship between LC connectivity across the whole brain and measures of anxiety and stress, with a particular focus on anxious arousal, a core feature of pathological anxiety. We assessed 77 individuals with and without anxiety or posttraumatic stress disorder (PTSD). We found that higher anxious arousal was robustly associated with higher LC connectivity to the dorsal anterior cingulate cortex (dACC). A conjunction analysis utilizing additional measures of anxiety and stress revealed consistent mapping of LC connectivity to the dACC and the insula (all p cluster < 0.05, FWE whole-brain corrected). This study leveraged high resolution functional connectivity mapping and individualized segmentation of the LC to demonstrate a consistent neuropathological phenotype of LC hyper-connectivity with dACC and insula across anxiety disorders and PTSD. These findings suggest that functional interactions between LC and dACC and insula represent a core aspect of pathological anxiety.

  • Open Access

    How Value and Control Shape Motivation: Dissociable Mesocorticolimbic Circuits and Ventromedial Prefrontal Cortex Dysfunction in Depression

    by Natalie Hackman, Philipp T. Neukam, Jacqueline Beltrán, Mu Li, Avijit Chowdhury, Michael T. Treadway, James W. Murrough, Laurel S. Morris

  • Open Access

    Structural imaging predictors of ketamine response in treatment-resistant depression: a machine learning approach

    by Linda Bryant, Laith Alexander, Sergio Mena, Yael Jacob, Jenna Jubeir, Mu Li, Philipp T. Neukam, Laurel S. Morris, James W. Murrough, Rebecca Price, et al.

    Ketamine has demonstrated rapid antidepressant efficacy in treatment-resistant depression (TRD), but clinical decision-making is challenging due to variability in individual response. Current trial-and-error prescribing practices may expose patients to ineffective treatment and avoidable adverse effects, underscoring the need for reliable predictive tools to optimize treatment selection and support personalized, evidence-based care. We developed a machine-learning model (support vector classifier) to predict antidepressant response to ketamine using pre-treatment structural MRI data. The model was trained on 99 adults with TRD given a single intravenous ketamine infusion (0.5 mg/kg). Clinical response was defined as a ≥50% reduction in MADRS scores 24 h post-infusion. Internal validation used repeated nested cross-validation, and generalizability was tested in two independent ketamine-treated cohorts ( n = 51) and a saline-treated control group ( n = 49). Among ketamine-treated participants, 52 (52.5%) responded to treatment. The model achieved a balanced accuracy of 72.2% (sensitivity = 72.3%, specificity = 73.1%, AUC = 0.72) in the discovery sample and 60.0% ( p = 0.01, AUC = 0.65) in external validation. Greater gray matter volume in frontal regions predicted response, whereas greater cerebellar volume predicted non-response. Performance dropped to chance in the saline cohort (BAC = 41.1%, AUC = 0.45), supporting pharmacologic specificity. These findings present the first machine-learning model for the prediction of ketamine response in TRD using structural neuroimaging and highlight its potential utility for stratified treatment planning and biomarker-informed interventions while providing mechanistic insight into neuroanatomical predictors of antidepressant response.

  • Open Access

    A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety

    by James Murrough, Rachel Fremont, Philipp Neukam, Usha Govindarajulu, Jessica Ables, Sara Hameed, Marcella Corwin, Mackenzie Hargrove, Helena Chang, Sarah Boukezzi, et al.

    Major Depressive Disorder (MDD) is a common and debilitating disease. Kv7 potassium channels are relevant to reward processing and represent a novel target for depression and anhedonia. Azetukalner is a positive allosteric modulator of Kv7. This phase II, randomized, double-blind, placebo-controlled trial assessed changes in brain reward function, clinical outcomes, and safety following treatment with azetukalner or placebo in individuals with MDD and anhedonia. The study included 60 participants with MDD and anhedonia in a current major depressive episode. Participants were randomized 1:1 to receive azetukalner (20 mg orally once daily with food) or placebo for 8 weeks. The primary endpoint was change in bilateral ventral striatum (VS) activity assessed by fMRI during a reward task from baseline to week 8. Secondary endpoints included changes in depression severity and anhedonia measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) and Snaith-Hamilton Pleasure Scale (SHAPS). Of 60 participants, 29 were randomized to azetukalner and 31 to placebo. There was no significant difference in VS response to reward anticipation between groups. Compared to placebo, azetukalner was associated with numerical benefit on the MADRS and SHAPS that did not reach statistical significance. Additional exploratory endpoints also favored azetukalner over placebo. Discontinuation rates due to adverse events were low and did not differ across groups. Despite not meeting the primary neuroimaging endpoint,secondary and exploratory outcomes suggested potential improvement in depressive and anhedonia symptoms, consistent with recent studies. Trial Registration: Clinicaltrials.gov ID NCT04827901


  • Open Access

    Arbitration between model-free and model-based control is not affected by transient changes in tonic serotonin levels

    by Maximilian D. Gilger, Lydia Hellrung, Philipp T. Neukam, Nils B. Kroemer, Stephan Nebe, Shakoor Pooseh, Yacila I. Deza-Lougovski, Michael N. Smolka

    Background: Serotonin has been suggested to modulate decision-making by influencing the arbitration between model-based and model-free control. Disruptions in these control mechanisms are involved in mental disorders such as drug dependence or obsessive-compulsive disorder. While previous reports indicate that lower brain serotonin levels reduce model-based control, it remains unknown whether increases in serotonergic availability might thus increase model-based control. Moreover, the mediating neural mechanisms have not been studied yet. Aim: The first aim of this study was to investigate whether increased/decreased tonic serotonin levels affect the arbitration between model-free and model-based control. Second, we aimed to identify the underlying neural processes. Methods: We employed a sequential two-stage Markov decision-task and measured brain responses during functional magnetic resonance imaging in 98 participants in a randomized, double-blind cross-over within-subject design. To investigate the influence of serotonin on the balance between model-free and model-based control, we used a tryptophan intervention with three intervention levels (loading, balanced, depletion). We hypothesized that model-based behaviour would increase with higher serotonin levels. Results: We found evidence that neither model-free nor model-based control were affected by changes in tonic serotonin levels. Furthermore, our tryptophan intervention did not elicit relevant changes in Blood-Oxygenation-Level Dependent activity.


  • Open Access

    Connection Failure: Differences in White Matter Microstructure are associated with 5-HTTLPR but not with Risk-Seeking for Losses

    by Philipp T. Neukam, Dirk K. Müller, Yacila I. Deza-Araujo, Shakoor Pooseh, Stephanie H. Witt, Marcella Rietschel, Michael N. Smolka

    In a previous study (Neukam, Kroemer et al. 2018), we found for the 5-HTTLPR genotype higher risk-seeking for losses in S/S vs. L/L carrier, which could not be explained by acutely changed central serotonin levels. This finding alternatively may be the result of reduced top-down control from the frontal cortex due to altered signal pathways involving the amygdala and ventral striatum. The serotonergic system is known to be involved in neurodevelopment and neuroplasticity. Therefore, the aim of this study was to investigate whether structural differences in white matter can explain the differences in risk-seeking behaviour that we observed in our previous study and whether 5-HTTLPR groups differ in their white matter microstructure. These differences can be detected using diffusion-weighted imaging (DWI). We assumed lower structural connectivity in S/S compared to L/L carrier, and a negative relationship between risk-seeking for losses and connectivity. We used DWI to compute diffusion parameters for the frontostriatal and uncinate tract in 175 individuals (39 S/S, 80 S/L, 56 L/L). Results showed no significant relationship between diffusion parameters and risk-seeking for losses. Furthermore, we did not find significant differences in diffusion parameters of the S/S vs. L/L group. There were only group differences in the frontostriatal tract showing stronger structural connectivity in the S/L group, which is also reflected in the whole brain approach. Therefore, the data do not support our hypothesis that the association between 5- HTTLPR and risk-seeking for losses is related to differences in white matter pathways implicated in decision-making.

  • Open Access

    A comparison of fMRI and behavioral models for predicting inter-temporal choices

    by Felix G. Knorr, Philipp T. Neukam, Juliane H. Fröhner, Holger Mohr, Michael N. Smolka, Michael Marxen


  • No evidence for the involvement of serotonin or the 5-HTTLPR genotype in intertemporal choice in a larger community sample

    by Philipp T Neukam, Yacila I Deza-Araujo, Michael Marxen, Shakoor Pooseh, Marcella Rietschel, Uwe Schwarzenbolz, Michael N Smolka

    Serotonin has been implicated in impulsive behaviours such as temporal discounting. While animal studies and theoretical approaches suggest that reduced tonic serotonin levels increase temporal discounting rates and vice versa, evidence from human studies is scarce and inconclusive. Furthermore, an important modulator of serotonin signalling, a genetic variation in the promoter region of the serotonin transporter gene (5-HTTLPR), has not been investigated for temporal discounting so far. First, the purpose of this study was to test for a significant association between 5-HTTLPR and temporal discounting. Second, we wished to investigate the effect of high/low tonic serotonin levels on intertemporal choice and blood oxygen-level-dependent response, controlling for 5-HTTLPR. We tested the association of 5-HTTLPR with temporal discounting rates using an intertemporal choice task in 611 individuals. We then manipulated tonic serotonin levels with acute tryptophan interventions (depletion, loading, balanced) in a subsample of 45 short (S)-allele and 45 long (L)/L-allele carriers in a randomised double-blind crossover design using functional magnetic resonance imaging and an intertemporal choice task. Overall, we did not find any effect of serotonin and 5-HTTLPR on temporal discounting rates or the brain networks associated with valuation and cognitive control. Our findings indicate that serotonin may not be directly involved in choices including delays on longer timescales such as days, weeks or months. We speculate that serotonin plays a stronger role in dynamic intertemporal choice tasks where the delays are on a timescale of seconds and hence are therefore directly experienced during the experiment.


  • Acute tryptophan loading decreases functional connectivity between the default mode network and emotion‐related brain regions

    by Yacila I. Deza‐Araujo, Philipp T. Neukam, Michael Marxen, Dirk K. Müller, Thomas Henle, Michael N. Smolka

    It has been shown that the functional architecture of the default mode network (DMN) can be affected by serotonergic challenges and these effects may provide insights on the neurobiological bases of depressive symptomatology. To deepen our understanding of this possible interplay, we used a double‐blind, randomized, cross‐over design, with a control condition and two interventions to decrease (tryptophan depletion) and increase (tryptophan loading) brain serotonin synthesis. Resting‐state fMRI from 85 healthy subjects was acquired for all conditions 3 hr after the ingestion of an amino acid mixture containing different amounts of tryptophan, the dietary precursor of serotonin. The DMN was derived for each participant and session. Permutation testing was performed to detect connectivity changes within the DMN as well as between the DMN and other brain regions elicited by the interventions. We found that tryptophan loading increased tryptophan plasma levels and decreased DMN connectivity with visual cortices and several brain regions involved in emotion and affect regulation (i.e., putamen, subcallosal cortex, thalamus, and frontal cortex). Tryptophan depletion significantly reduced tryptophan levels but did not affect brain connectivity. Subjective ratings of mood, anxiety, sleepiness, and impulsive choice were not strongly affected by any intervention. Our data indicate that connectivity between the DMN and emotion‐related brain regions might be modulated by changes in the serotonergic system. These results suggest that functional changes in the brain associated with different brain serotonin levels may be relevant to understand the neural bases of depressive symptoms.